University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...

DNA analysis is a crucial tool for identifying harmful pathogens, such as bacteria, viruses, or fungi, that cause infections.

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Menopausal hormone therapy did not elevate risk for breast cancer among women with inherited BRCA ...

Please provide your email address to receive an email when new articles are posted on . Age at diagnosis did not affect survival among young women with breast cancer with BRCA mutations. DFS and OS ...

(NEXSTAR) — An unexpected delivery at your door may not always be an unwelcome surprise — just ask one Kentucky boy about the thousands of dollars worth of lollipops that arrived at his home earlier ...

BREAST CANCER SURGERY. ACCORDING TO A GENETIC COUNSELOR AT MERCY MEDICAL CENTER, YOUR CHANCE OF DEVELOPING BREAST CANCER WITHOUT A FAMILY HISTORY OR NO OTHER SPECIAL CIRCUMSTANCE IS ABOUT 12%. THE ...

VANESSA THANK YOU. AND NOW TO THE STORY OF A WOMAN WHO IS NOT ONLY A BREAST CANCER ADVOCATE, SHE’S AN AUTHOR AND NOW A MOVIE PRODUCER. HER FIRST FULL LENGTH FILM TACKLES THE DECISIONS A WOMAN WITH A ...

Navigating a cancer diagnosis can be both a devastating and empowering experience. Having a village to help you move through doctors’ appointments, excruciating pain, treatment, and the unnerving ...

A Long Island nurse is sharing a message of action in the face of a frightening genetic finding. She learned she was positive for the BRCA mutation, which increases the risk of cancers, but she took ...

Quality of care (QoC) measures among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment: A SEER-Medicare analysis.